Value Partners, Insilico Medicine Plan AI, Life Sciences CVC Fund

MT Newswires Live
08/19

Value Partners Group (HKG:0806), Insilico Medicine (HKG:3696), Shanghai Pudong Development Group, and Pudong Construction plan to jointly establish a RMB-denominated corporate venture capital fund.

The fund will focus on artificial intelligence and life sciences, according to a statement on Tuesday.

Value Partners' onshore private fund manager will serve as the fund's general partner and manager.

The parties plan to combine capital and industry resources to invest across the AI and life sciences ecosystem.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10